News | January 03, 2025
Veeda Group rebrands as Veeda Lifesciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Subscribe To Our Newsletter & Stay Updated
